Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics
Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic
https://finance.yahoo.com/news/allarity-therapeutics-oncoheroes-biosciences-sign-130000918.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.